IDHQ - ETF AI Analysis

Top Page

Invesco S&P International Developed High Quality ETF (IDHQ)

Rating:64Neutral

Price Target:―

IDHQ’s rating suggests it is a solid-quality international ETF, mainly driven by strong, financially sound companies like Novartis and ASML, which show robust growth, healthy balance sheets, and supportive long-term prospects. However, some holdings such as Airbus and Unilever face bearish market momentum or valuation concerns, and several top positions show signs of potential overvaluation, making price risk and sector-specific challenges important factors to watch.

Positive Factors

Strong Recent Performance

The ETF has shown steady gains over the past month, three months, and year-to-date, indicating positive recent momentum.

High-Quality Leading Holdings

Several of the largest positions, including major technology and industrial names, have delivered strong year-to-date performance that supports the fund’s returns.

Broad International Diversification

Holdings spread across many developed countries and sectors help reduce the impact of weakness in any single market or industry.

Negative Factors

Moderate Fee Level

The expense ratio is not especially low, so costs may be higher than some cheaper index ETFs and can slightly reduce long-term returns.

Sector Concentration in Industrials and Financials

A large share of assets in industrial and financial companies means the fund could be more sensitive if these sectors face a downturn.

Exposure to Some Lagging Top Holdings

A few of the largest positions, such as certain financial and consumer stocks, have shown weaker year-to-date performance that can drag on overall results.

IDHQ vs. SPDR S&P 500 ETF (SPY)

AUM687.80M

RegionDeveloped Markets

Expense Ratio0.29%

Beta0.70

IssuerInvesco

Inception DateJun 13, 2007

Dividend Yield2.24%

Asset ClassEquity

Index TrackedS&P Quality Developed Ex-U.S. LargeMidCap Index

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume105,571

30 Day Avg. Volume88,058

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

41.88

Price Target Upside― Downside

Rating ConsensusModerate Buy

Number of Analyst Covering178

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

IDHQ Summary

IDHQ is an ETF that follows the S&P Quality Developed Ex-U.S. LargeMidCap Index, focusing on high-quality companies in developed countries outside the U.S. It holds well-known names like ASML Holding and Novartis, and invests across many sectors, including industrials, technology, and health care, with large exposure to markets such as Japan, the UK, and Switzerland. Someone might invest in IDHQ to diversify beyond the U.S. and seek long-term growth from financially strong international companies. A key risk is that international stock prices can go up and down with global markets and currency movements.

How much will it cost me?The Invesco S&P International Developed High Quality ETF (IDHQ) has an expense ratio of 0.29%, which means you’ll pay $2.90 per year for every $1,000 invested. This is slightly higher than average for passively managed ETFs because it focuses on a specialized strategy of selecting high-quality international companies. The added cost reflects the fund's meticulous approach to targeting financially strong firms.

What would affect this ETF?Positive drivers for IDHQ include potential growth in developed markets outside the U.S., particularly in sectors like healthcare and technology, which are heavily weighted in the ETF and often benefit from innovation and stable demand. However, negative factors could arise from global economic slowdowns, regulatory changes in key regions, or currency fluctuations that impact international companies' profitability. The ETF's focus on high-quality companies may help mitigate risks but does not eliminate exposure to broader market challenges.

IDHQ Top 10 Holdings

IDHQ leans heavily on a handful of international heavyweights, with Dutch chip-equipment maker ASML and Japan’s Advantest powering returns as the semiconductor story keeps humming. Health care is another key engine: Swiss giants Roche, Novartis, and UK-based GSK have been steadily rising, giving the fund a defensive backbone with a growth twist. Industrial names like ABB and Rolls-Royce add extra lift, though their momentum has been a bit more mixed. Overall, the ETF is firmly ex-U.S., tilted toward developed European and Asian markets rather than homegrown U.S. tech titans.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
ASML	ASML Holding NV	5.97%	$41.31M	€475.49B	77.75%	76 Outperform
ROG	Roche Holding AG	4.52%	$31.30M	CHF294.84B	43.28%	73 Outperform
NOVN	Novartis AG	4.42%	$30.56M	CHF242.43B	30.05%	80 Outperform
6857	Advantest	3.42%	$23.64M	¥18.81T	145.98%	75 Outperform
SAF	SAFRAN SA	2.95%	$20.44M	€142.86B	42.82%	67 Neutral
RR	Rolls-Royce Holdings	2.95%	$20.40M	£111.64B	135.88%	71 Outperform
ULVR	Unilever	2.58%	$17.85M	£116.19B	8.30%	72 Outperform
ALV	Allianz	2.54%	$17.55M	€141.06B	17.46%	67 Neutral
GSK	GlaxoSmithKline	2.27%	$15.68M	£91.50B	51.88%	77 Outperform
ABB	ABB Ltd	2.26%	$15.64M	kr1.51T	37.24%	78 Outperform

IDHQ Technical Analysis

Technical Analysis Sentiment

Positive

Last Price―

Price Trends

50DMA

36.80

Positive

100DMA

35.50

Positive

200DMA

33.89

Positive

Market Momentum

MACD

0.62

Positive

RSI

63.85

Neutral

STOCH

81.29

Negative

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IDHQ, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 38.26, equal to the 50-day MA of 36.80, and equal to the 200-day MA of 33.89, indicating a bullish trend. The MACD of 0.62 indicates Positive momentum. The RSI at 63.85 is Neutral, neither overbought nor oversold. The STOCH value of 81.29 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IDHQ.

IDHQ Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
IDHQ	―	―	$687.80M	0.29%	64 Neutral
TLTD	―	―	$648.04M	0.39%	64 Neutral
FYLD	―	―	$595.94M	0.59%	61 Neutral
AVSD	―	―	$452.04M	0.23%	65 Neutral
MFDX	―	―	$447.53M	0.39%	65 Neutral
TXUE	―	―	$383.39M	0.65%	63 Neutral

Performance Comparison

IDHQ

Invesco S&P International Developed High Quality ETF

38.96

8.74

28.92%

TLTD

FlexShares Morningstar Developed Markets ex-US Factor Tilt

―

FYLD

Cambria Foreign Shareholder Yield ETF

―

AVSD

Avantis Responsible International Equity ETF

―

MFDX

PIMCO RAFI Dynamic Multi-Factor International Equity ETF

―

TXUE

Thornburg International Equity ETF

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents